Related Experiment Videos
Molecular mechanisms of pulmonary fibrosis
1Facultad de Ciencias, Universidad Nacional Autónoma de Mexico. Apartado Postal 21-630. Coyoacan, México DF, 04000.
Abstract:
Pulmonary fibrosis is the end-point of a numerous and heterogeneous group of disorders known as interstitial lung diseases (ILD). Lung fibrotic remodeling is characterized by fibroblast/myofibroblast activation, and excessive extracellular matrix accumulation leading to progressive organ dysfunction and usually terminal outcome. Treatment is largely ineffective primarily because few of the molecular mechanisms have been well defined to design appropriate targets for therapy. While the pathogenesis is incompletely understood, a growing body of evidence suggests two different pathogenic routes for developing pulmonary fibrosis. The inflammatory pathway, where a shift to the so-called T-helper 2 type cytokine networks is critical, and the epithelial pathway represented by idiopathic pulmonary fibrosis, by far the most aggressive ILD. In this pathway the inflammatory process is irrelevant, and the physiopathology seems to be dominated by epithelial cell injury and activation. Both routes may trigger a number of cytokines/growth factors inducing fibroblast migration/proliferation and phenotype change to myofibroblasts, with a consequent accumulation of extracellular matrix. An imbalance in matrix metalloproteinase/tissue inhibitors of metalloproteinases may contribute to alteration in extracellular matrix turnover and remodeling. This review will focus in some of the mechanisms involved in both prefibrotic pathways, as well as those involved in fibroblast activation and abnormal matrix deposition.
Insights
Pulmonary fibrosis, a severe lung disease, results from fibroblast activation and excessive matrix buildup. Understanding its inflammatory and epithelial pathways is crucial for developing effective treatments for interstitial lung diseases.
Area of Science:
- Pulmonary and cellular biology
- Pathogenesis of fibrotic lung disease
Background:
- Pulmonary fibrosis, the end-stage of interstitial lung diseases (ILDs), involves fibroblast activation and excessive extracellular matrix accumulation, leading to organ dysfunction.
- Current treatments for pulmonary fibrosis are largely ineffective due to poorly understood molecular mechanisms.
- Idiopathic pulmonary fibrosis (IPF) is the most aggressive ILD, characterized by epithelial cell injury and activation, independent of inflammation.
Purpose of the Study:
- To review the mechanisms underlying pulmonary fibrosis, focusing on two distinct pathogenic pathways: inflammatory and epithelial.
- To explore the processes of fibroblast activation and abnormal matrix deposition in fibrotic lung remodeling.
Main Methods:
- Review of existing literature on the pathogenesis of pulmonary fibrosis.
- Analysis of molecular mechanisms, including cytokine signaling and extracellular matrix turnover.
Main Results:
- Two primary pathogenic routes for pulmonary fibrosis identified: an inflammatory pathway (Th2-cytokine driven) and an epithelial pathway (dominant in IPF).
- Both pathways converge to activate fibroblasts, promote myofibroblast differentiation, and lead to excessive extracellular matrix deposition.
- Imbalances in matrix metalloproteinases and their inhibitors may contribute to altered matrix remodeling.
Conclusions:
- Understanding the distinct molecular mechanisms of inflammatory and epithelial pathways is essential for targeted therapeutic strategies against pulmonary fibrosis.
- Further research into fibroblast activation and matrix deposition is critical for improving treatment outcomes in interstitial lung diseases.